WILMINGTON, Del.–(BUSINESS WIRE)–Feb. 27, 2024– Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy. The Prescription Drug User Fee Act (PDUFA) date for the FDA decision is August 28, 2024.
Resources
Incyte Announces US FDA Grants Priority Review For Axatilimab For Chronic GVHD Treatment
